TITLE

Endocrine and Metabolic Manifestations on Invasive Fungal Infections and Systemic Antifungal Treatment

AUTHOR(S)
Lionakis, Michail S.; Samonis, George; Kontoyiannis, Dimitrios P.
PUB. DATE
September 2008
SOURCE
Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p1046
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Systemic fungal Infections are increasingly reported in immuno-compromised patients with hematological malignancies, recipients of bone marrow and solid organ allografts, and patients with AIDS. Mycoses may infiltrate endocrine organs and adversely affect their function or produce metabolic complications, such as hypopituitarism, hyperthyroidism or hypothyroidism, pancreatitis, hypoadrenalism, hypogonadism, hypernatremia or hyponatremia, and hypercalcemia. Antifungal agents used for prophylaxis and/or treatment of mycoses also have adverse endocrine and metabolic effects, including hypoadrenalism, hypogonadism, hypoglycemia, dyslipidemia, hypernatremia, hypocalcemia, hyperphosphatemia, hyperkalemia or hypokalemia, and hypomagnesemia. Herein, we review how mycoses and conventional systemic antifungal treatment can affect the endocrine system and cause metabolic abnormalities. If clinicians are equipped with better knowledge of the endocrine and metabolic complications of fungal Infections and antifungal therapy, they can more readily recognize them and favorably affect outcome.
ACCESSION #
34205911

 

Related Articles

  • Addition of high-dose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Mineishi, S; Longo, W L; Atkinson, M E; Smith, E P; Hamielec, M; Wiersma, S R; Kinsella, T J; Schuening, F G // Bone Marrow Transplantation;6/15/99, Vol. 23 Issue 12, p1217 

    The optimal conditioning regimen for allogeneic BMT for hematological malignancies is still to be determined. We used a conditioning regimen including high-dose Ara-C (HDAC)/CY/TBI for patients at high risk for leukemic relapse (regimen A, Ara-C 3 g/m2 every 12 h for six doses followed by CY 45...

  • Bone Marrow Involvement in a Patient with Paracoccidioidomycosis: A Rare Presentation of Juvenile Form. Pereira, Graziella Hanna; Santos, Aline Queiroz; Park, Miriam; Muller, Patricia Rady; Padua, Soraia; Marchesi, Raquel Ferrari; Aldred, Vera Lucia // Mycopathologia;Oct2010, Vol. 170 Issue 4, p259 

    Paracoccidioides brasiliensis rarely shows bone marrow involvement and its response to treatment with itraconazole in children needs further assessment. We describe here a child with a juvenile disseminated form of paracoccidioidomycosis, which showed reticuloendothelial system involvement and...

  • Therapeutic Approaches to Subcutaneous Mycoses. Koga, Tetsuya; Matsuda, Tetsuo; Matsumoto, Tadahiko; Furue, Masutaka // American Journal of Clinical Dermatology;2003, Vol. 4 Issue 8, p537 

    Subcutaneous mycoses, which are much less common than superficial fungal infections, are characterized by a heterogeneous group of infections that often result from direct penetration of the fungus into the dermis and subcutaneous tissue through traumatic injury. The fungus spreads by local deep...

  • Clinico-Investigative Profile and Anti-Fungal Susceptibility of Fungemia Cases in Haematological Malignancy Patients. Agarwal, Isha; Capoor, Malini R.; Hamidi, Ahsaan; Mohindera, Ritin; Gupta, D. K. // New Indian Journal of Surgery;Oct2011, Vol. 2 Issue 4, p262 

    The incidence of deep fungal infections in patients with malignancies has increased dramatically over the past decades. Majority of these infections occur in patients with hematologic malignancies due to a multitude of predisposing risk factors. However over the years due to antifungal...

  • A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Oren, I.; Rowe, J. M.; Sprecher, H.; Tamir, A.; Benyamini, N.; Akria, L.; Gorelik, A.; Dally, N.; Zuckerman, T.; Haddad, N.; Fineman, R.; Dann, E. J. // Bone Marrow Transplantation;Jul2006, Vol. 38 Issue 2, p127 

    Fluconazole antifungal prophylaxis is standard care in allogeneic hematopoietic stem cell transplant (HSCT) recipients, but this drug lacks anti-Aspergillus activity, the primary cause of invasive fungal infection (IFI) in many transplantation centers. We performed a randomized trial to compare...

  • Alternaria alternata Invasive Fungal Infection in a Patient with Fanconi's Anemia after an Unrelated Bone Marrow Transplant. Ferreira, Isabelina; Teixeira, Gilda; Abecasis, Manuel // Clinical Drug Investigation;Feb2013 Supplement, Vol. 33, p33 

    Alternaria spp. have emerged as opportunistic pathogens particularly in immunosuppressed patients, such as bone marrow transplant recipients. The authors present a case of Alternaria alternata in a patient with Fanconi's anemia, who received antifungal prophylaxis with posaconazole after an...

  • A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Imataki, O.; Kami, M.; Kim, S-W.; Gotoh, M.; Komaba, S.; Kasai, M.; Hashino, S.; Naito, K.; Masuda, M.; Anan, K.; Teshima, H.; Togitani, K.; Inoue, T.; Nishimura, M.; Adachi, Y.; Fukuhra, T.; T.Yamashita; Uike, N.; Kobayashi, Y.; Hamaguchi, M. // Bone Marrow Transplantation;Jun2004, Vol. 33 Issue 12, p1173 

    Summary:We conducted a nationwide survey to define incidence of deep fungal infections and fungal prophylaxis practices after HSCT. In all, 63 institutions responded. Total number of in-patient transplantations was 935: 367 autologous, 414 allogeneic myeloablative, and 154 allogeneic...

  • Mucosal and Systemic Fungal Infections in Patients with AIDS: Prophylaxis and Treatment. Ruhnke, Markus // Drugs;2004, Vol. 64 Issue 11, p1163 

    In countries where highly active antiretroviral therapy (HAART) is widely available, a decrease in the incidence of fungal infections has been observed in the last 5 years compared with countries that cannot afford this treatment. Even refractory fungal infections may be controlled when HAART is...

  • Posaconazole is not superior to itraconazole for fungal prophylaxis in allogeneic blood and marrow transplantation. Mossad, S B // Bone Marrow Transplantation;Oct2012, Vol. 47 Issue 10, p1379 

    A letter to the editor is presented in response to the article "Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation" by I. Saánchez-Ortega and colleagues in the 2012 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics